How to Decide Between a SPAC and a Traditional IPO: A Decision Framework Based on Size and Sector

The decision between a traditional initial public offering and a de-SPAC merger is no longer a theoretical choice for private companies targeting a US listing. It is a structural question with material implications for valuation certainty, timeline, and dilution, particularly following the US Securities and Exchange Commission’s (SEC) adoption of new SPAC rules in January 2024. These rules, codified in SEC Release No. 33-11265, reclassified SPAC business combinations as effectively equivalent to IPOs for liability purposes under the Securities Act of 1933, eliminating the safe harbour for forward-looking statements that had been a key attraction of the SPAC route. This regulatory recalibration, combined with a sharp contraction in SPAC issuance—only 27 new SPAC IPOs raised USD 2.7 billion in 2024, down from a peak of 613 SPACs raising USD 162.6 billion in 2021 (SPAC Research, 2025)—has forced sponsors and target companies to re-evaluate the frameworks governing their listing strategy. The choice now hinges on five discrete variables: enterprise value, sector, revenue visibility, regulatory timeline, and the cost of capital. This article provides a decision framework, grounded in 2024-2025 market data and US securities law mechanics, to guide CFOs and sponsors through the trade-offs.

The Size Threshold: Where the Calculus Shifts

Enterprise value is the single most predictive variable in determining whether a traditional IPO or a SPAC route is viable. The data from 2024 US listings shows a clear bifurcation point at approximately USD 500 million in pre-money equity value.

The USD 500 Million Inflection Point

A traditional IPO on the NYSE or NASDAQ requires sufficient institutional demand to support a price discovery process that typically results in a 15-25% first-day pop for high-quality issuers (Renaissance Capital, 2024). For companies with a pre-money equity value below USD 300 million, the fixed costs of the IPO process—underwriting fees averaging 5.5-7.0% of gross proceeds, legal fees of USD 2-4 million, and auditor diligence costs of USD 1-2 million—consume a disproportionate share of the offering proceeds. In 2024, the median traditional IPO on US exchanges raised USD 87 million (Dealogic, 2025). At that size, the SPAC route, which typically involves a PIPE (private investment in public equity) of USD 50-150 million to backstop the trust, becomes structurally more efficient. For issuers above USD 1 billion in enterprise value, the traditional IPO offers superior pricing precision and lower ongoing sponsor costs, as SPACs require sponsor promote shares that dilute existing holders by 20-25% on average (SEC Release 33-11265, 2024).

Sector-Specific Size Dynamics

The sector in which the target operates interacts with the size threshold in a non-linear fashion. Technology and life sciences issuers, which often have negative EBITDA at the time of listing, are disproportionately represented in the SPAC pipeline. In 2024, 68% of de-SPAC transactions involved companies with negative trailing twelve-month net income (SPAC Research, 2025). For these issuers, the SPAC’s ability to provide a forward-looking valuation based on projected revenue—even under the stricter SEC liability regime—remains more attractive than the historical financials focus of a traditional IPO. Conversely, issuers in financial services, energy, and industrials, where investors demand audited historical margins and comparable public company multiples, overwhelmingly choose the traditional IPO. In 2024, no SPAC merger was completed for a financial services company with a market capitalisation above USD 1 billion, while 14 such companies completed traditional IPOs (NYSE and NASDAQ filings, 2024-2025).

The Regulatory and Liability Framework

The SEC’s January 2024 rulemaking fundamentally altered the liability landscape for SPACs, removing the primary advantage that had driven their 2020-2021 boom.

The End of the Safe Harbour

Before 2024, SPACs could rely on the Private Securities Litigation Reform Act (PSLRA) safe harbour for forward-looking statements made in proxy statements and registration statements. SEC Release 33-11265 explicitly revoked this protection, holding that de-SPAC transactions are functionally equivalent to a traditional IPO and therefore subject to Section 11 strict liability under the Securities Act of 1933. This means that any material misstatement or omission in the proxy statement or registration statement exposes the SPAC sponsor, the target company, and its directors to unlimited liability. The practical consequence is that SPAC sponsors now face the same due diligence burden as traditional IPO underwriters. In 2024, at least three de-SPAC transactions were abandoned after the sponsor’s legal counsel advised that the due diligence required to meet the new standard would exceed the time and cost savings that the SPAC route was supposed to provide (SEC EDGAR filings, 2024).

The Impact on Sponsor Economics

The new liability framework has compressed sponsor promote structures. Before 2024, the typical sponsor promote was 20% of the post-IPO equity, often structured as founder shares purchased for USD 25,000. Under the new regime, sponsors are increasingly accepting promotes of 10-15% to align their risk with that of public shareholders. Data from 2024 shows that the average sponsor promote in completed de-SPAC transactions was 13.4%, down from 21.8% in 2021 (SPAC Research, 2025). This compression makes the SPAC route more attractive for target companies, as it reduces dilution for existing shareholders. However, it also reduces the sponsor’s incentive to pursue marginal transactions, as the risk-adjusted return on the sponsor’s capital (typically USD 5-10 million in underwriting and legal fees) now requires a higher probability of success.

The Timeline and Certainty Trade-Off

The traditional IPO process, from confidential filing to pricing, typically takes 6-9 months for a well-prepared issuer. The SPAC route, from signing a definitive agreement to closing, averages 4-6 months. But these headline numbers mask significant variance.

The Certainty of Pricing vs. Certainty of Closing

A traditional IPO offers pricing certainty only at the end of the bookbuilding process, which can be withdrawn if market conditions deteriorate. In 2024, 22% of US IPO filings were withdrawn or postponed (Renaissance Capital, 2024). A SPAC transaction, by contrast, offers a fixed valuation at signing, subject only to shareholder approval and regulatory clearance. However, the SPAC route introduces execution risk from the trust redemption mechanism. In 2024, the average redemption rate in de-SPAC transactions was 62.4%, meaning that only 37.6% of the SPAC trust proceeds remained at closing (SPAC Research, 2025). For a target company relying on the trust for its primary capital, a high redemption rate can leave it undercapitalised, forcing it to raise a PIPE on unfavourable terms. The decision framework must therefore weigh the pricing certainty of a SPAC against the capital certainty of a traditional IPO, where the underwriter provides a firm commitment to purchase the shares.

The Role of PIPE Commitments

PIPE investors have become the critical backstop in the SPAC ecosystem. In 2024, the median PIPE as a percentage of the trust was 35%, down from 50% in 2021 (Dealogic, 2025). PIPE investors typically receive warrants or rights that provide a 10-20% upside premium, but they also face the same lock-up restrictions as the target’s existing shareholders. For a target company considering the SPAC route, the strength and reputation of the PIPE investors is a more important factor than the SPAC sponsor’s track record. A PIPE anchored by a major asset manager—such as BlackRock, Fidelity, or Wellington—provides a signal of institutional validation that can support the stock price post-merger. In 2024, de-SPAC transactions with PIPE commitments from at least one top-20 asset manager had a 30-day post-merger return of +8.2%, compared to -14.7% for those without such a PIPE (SPAC Research, 2025).

Sector-Specific Considerations

The decision framework must incorporate sector-specific regulatory and investor dynamics that are not captured by size alone.

Life Sciences: The SPAC Advantage Persists

Life sciences companies, particularly those in clinical-stage drug development, face a structural challenge in the traditional IPO market: they have no approved products, no revenue, and a path to profitability that is 3-5 years away. The US IPO market has historically been receptive to these stories, but the 2022-2023 bear market reduced life sciences IPO volumes by 70% from 2021 levels (Evaluate Pharma, 2024). SPACs offer a solution by providing a public vehicle that can raise additional capital through at-the-market (ATM) offerings and follow-on offerings without the stigma of a distressed IPO. In 2024, five of the seven life sciences de-SPAC transactions involved companies that had previously attempted and failed to complete a traditional IPO (SEC EDGAR filings, 2024). The SPAC route allows these companies to access the public markets at a valuation that reflects their pipeline milestones, rather than their current financials.

Financial Services: The Traditional IPO Dominates

Financial services companies—banks, insurers, asset managers, and fintech firms—are required by US banking regulators and state insurance commissioners to maintain minimum capital ratios and demonstrate a track record of regulatory compliance. These requirements make the SPAC route impractical, as the de-SPAC process introduces uncertainty about the final capital structure. In 2024, no US-listed financial services company completed a de-SPAC transaction, while 18 completed traditional IPOs (NYSE and NASDAQ filings, 2024). The Hong Kong context reinforces this pattern: HKEX Main Board listing rules require financial institutions to provide three years of audited financial statements under HKFRS or IFRS, a standard that is incompatible with the forward-looking projections that SPACs typically rely upon. For Hong Kong-based financial services companies considering a US listing, the traditional IPO remains the only viable path.

The Hong Kong Cross-Border Angle

For Hong Kong-based private companies and family offices evaluating a US listing, the choice between a SPAC and a traditional IPO carries additional jurisdictional considerations.

The VIE Structure and SPACs

Companies with a variable interest entity (VIE) structure—common among PRC-based technology companies—face heightened scrutiny in a de-SPAC transaction. The SEC’s 2024 rules require SPACs to disclose the legal and regulatory risks associated with VIE structures, including the potential for PRC government intervention. In 2024, two de-SPAC transactions involving PRC VIE targets were abandoned after the SEC requested additional disclosure regarding the enforceability of the VIE contracts (SEC comment letters, 2024). For a Hong Kong-incorporated company that does not use a VIE structure, this issue does not arise. However, for a Cayman or BVI-incorporated company with PRC operations, the traditional IPO route, which has a more established disclosure framework for VIE structures, is preferable.

The Role of the HKMA and SFC

Hong Kong-based sponsors and investment banks involved in US SPAC transactions must comply with the SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission, which requires sponsors to conduct adequate due diligence on any transaction they advise. The SFC’s 2023 circular on sponsor due diligence specifically addressed cross-border SPAC transactions, reminding sponsors that the standard of care required under Hong Kong law is independent of the US regulatory framework. For a Hong Kong sponsor advising a PRC target on a US SPAC merger, the due diligence burden is effectively additive: the sponsor must satisfy both the SEC’s requirements under Release 33-11265 and the SFC’s requirements under the Code of Conduct. This dual regulatory burden can add 2-3 months to the timeline and USD 500,000 to USD 1 million in legal and advisory costs.

Actionable Takeaways

1. For companies with a pre-money equity value below USD 500 million and negative EBITDA, the SPAC route offers a more predictable timeline and valuation, but only if a top-20 asset manager anchors the PIPE.
2. The SEC’s January 2024 rules have eliminated the forward-looking statement safe harbour for SPACs, making the due diligence burden equivalent to a traditional IPO—any time savings are now purely procedural, not legal.
3. Life sciences and technology issuers should prioritise SPACs for their ability to price on pipeline milestones; financial services and industrial issuers should default to the traditional IPO.
4. Hong Kong-based sponsors advising on US SPAC transactions must budget for dual SFC and SEC due diligence requirements, adding approximately USD 750,000 in incremental costs.
5. The redemption rate in de-SPAC transactions averaged 62.4% in 2024—any target company considering a SPAC must secure a PIPE commitment of at least 35% of the trust to ensure adequate capitalisation at closing.